COMPUGEN LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.13 USD | -3.62% |
|
+7.04% | +7.58% |
| Mar. 08 | Truist Securities Adjusts Price Target on Compugen to $5 From $4, Maintains Buy Rating | MT |
| Mar. 05 | Transcript : Compugen Ltd., Q4 2023 Earnings Call, Mar 05, 2024 |
Presenter SpeechMark Breidenbach (Analysts)All right. So it's 9:10. Let's go ahead and get sta...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.
Calendar
2024-05-20
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
2.13
USD
Average target price
5.333
USD
Spread / Average Target
+150.39%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +7.58% | 191M | |
| +22.56% | 46.71B | |
| -1.51% | 41.52B | |
| +48.83% | 41.8B | |
| -3.42% | 29.55B | |
| +10.13% | 25.78B | |
| -20.44% | 19.26B | |
| +26.45% | 11.98B | |
| -0.14% | 12.14B | |
| -0.47% | 12.08B |
- Stock Market
- Equities
- CGEN Stock
- News Compugen Ltd.
- Transcript : Compugen Ltd. Presents at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit, Sep-22-2020 09